Rania H. Younis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rania H. Younis has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Donita Dyalram
Department of Oral and Maxillofacial Surgery, University of Maryland School of Dentistry, Baltimore, MD, United States
5 shared publicationsJohn C. Papadimitriou
Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, United States
5 shared publicationsJoshua E. Lubek
Department of Oral and Maxillofacial Surgery, University of Maryland School of Dentistry, Baltimore, MD, United States
5 shared publicationsRobert A. Ord
Department of Oral and Maxillofacial Surgery, University of Maryland School of Dentistry, Baltimore, MD, United States
5 shared publications- Tonya J. Webb
Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
5 shared publications Ioana Ghita
Department of Oncology and Diagnostic Sciences, Division of Oral and Maxillofacial Pathology, University of Maryland School of Dentistry, Baltimore, MD, United States
4 shared publications
Latest Publications
- Open Access
- 20 May 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (5) , 749
Natural Killer T Cell Function in Lymphoma Patients
Natural killer T (NKT) cells bridge innate and adaptive immune responses and play a critical role in anti-tumor immunity. The goal of the study was to assess NKT cell and T cell function in lymphoma patients and to investigate whether specific cytokines correlate with outcomes and/or immune cell function. Patient diagnoses were confirmed by histology. NKT and T cell number and function were assessed by flow cytometry and stimulation with artificial antigen-presenting cells (aAPCs) followed by ELISA and quantitative RT-PCR (qPCR). Cytokine expression levels were compared using online databases, and protein levels in the plasma were assessed by ELISA. NKT cell activation, indicated by at least 1.5-fold IFN-γ induction over baseline following stimulation, was detected in 82% of healthy donors, compared to 44% of lymphoma patients. Lymphoma patients have significantly higher levels of circulating pro- and anti-inflammatory cytokines IL-10, IL-6, and Sema4D as compared to healthy donors. In addition, NKT cell function in the blood correlated with NKT cell function in the bone marrow in lymphoma patients. We found that aAPC-qPCR can be used to quickly assess immune cell function in cancer patients. Circulating NKT cell function positively correlated with bone marrow NKT cell function, suggesting that circulating NKT responses reflect systemic immune competence. Outcome-associated transcriptomic analyses showed that lower expression of TGF-β, IL-6, IL-10, and IFN-γ mRNA correlated with poorer clinical outcomes, whereas higher Sema4D expression was associated with worse prognosis, identifying Sema4D as a potential immunologic biomarker linked to disease progression and immune dysfunction in B cell lymphoma.
- 20 May 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (5) , 749
Open AccessNatural Killer T Cell Function in Lymphoma Patients
Natural killer T (NKT) cells bridge innate and adaptive immune responses and play a critical role in anti-tumor immunity. The goal of the study was to assess NKT cell and T cell function in lymphoma patients and to investigate whether specific cytokines correlate with outcomes and/or immune cell function. Patient diagnoses were confirmed by histology. NKT and T cell number and function were assessed by flow cytometry and stimulation with artificial antigen-presenting cells (aAPCs) followed by ELISA and quantitative RT-PCR (qPCR). Cytokine expression levels were compared using online databases, and protein levels in the plasma were assessed by ELISA. NKT cell activation, indicated by at least 1.5-fold IFN-γ induction over baseline following stimulation, was detected in 82% of healthy donors, compared to 44% of lymphoma patients. Lymphoma patients have significantly higher levels of circulating pro- and anti-inflammatory cytokines IL-10, IL-6, and Sema4D as compared to healthy donors. In addition, NKT cell function in the blood correlated with NKT cell function in the bone marrow in lymphoma patients. We found that aAPC-qPCR can be used to quickly assess immune cell function in cancer patients. Circulating NKT cell function positively correlated with bone marrow NKT cell function, suggesting that circulating NKT responses reflect systemic immune competence. Outcome-associated transcriptomic analyses showed that lower expression of TGF-β, IL-6, IL-10, and IFN-γ mRNA correlated with poorer clinical outcomes, whereas higher Sema4D expression was associated with worse prognosis, identifying Sema4D as a potential immunologic biomarker linked to disease progression and immune dysfunction in B cell lymphoma.
- Open Access
- 16 June 2025
- Published by Frontiers Media SA in Frontiers in Oral Health
- Vol. 6, 1635675
Editorial: Immuno-oncologic biomarker signatures for personalized immunotherapy and immunoprevention in oral squamous cell carcinoma
The development of oral cancer is a multifactorial and complex process (1). The interaction between the mutated oral epithelial cells and the underlying stromal and immune system plays a major role in the process of tumor development and progression. Immunotherapy represents the most recent therapeutic advent in the field with significant improvement in overall survival. Yet, differential patients' responses warrants more understanding of the immuno-oncologic profile of oral cancer.The current research topic in Frontiers oral health-oral cancer aimed to shed light on recent evidence-based immuno-oncologic biomarkers associated with the clinico-pathological features of oral squamous cell carcinoma (OSCC) and potentially cancerous oral lesions. The ultimate goal is for better patients' stratification, and hence more guidance for personalized therapeutic regimens (2).The topic starts with a research manuscript by Sahu et al, titled: 4-Nitroquinoline 1-oxide induces immune cells death to onset early immunosuppression during Oral Squamous Cell Carcinoma Development. In this manuscript the authors present an in vivo model of how the chemical carcinogen modulates an immunosuppressive profile that starts in the oral precancerous stages. Significant decrease in B and T cell populations, specifically CD5+B cell, and gamma/delta-T cell population (γδ-TCR + ) was observed in the spleen in the early stages of development of the precancerous lesions and persisted after OSCC development. Despite the increase in NK, NKT, and lymphoid DC, in peripheral blood there was a decrease in most of the lymphocyte population (T, B, CD5+B cells) during early development, but not later. Concluding that immune cell derangement is not a post-cancerous event, rather, an early event that may persist until tumor development and beyond. In vitro analysis demonstrated B cells to be more susceptible to reduced viability and DNA damage when expos ed to the chemical carcinogen compared to T cells. These findings provide supportive pre-clinical evidence for introducing immunotherapy in initial stages of precancerous lesions, as a preventive strategy for OSCC.To further highlight the onset of immune derangement early in OSCC precursor lesions, the second research manuscript by Hanroongsri, et al, titled: Expression of PD-L1 and p-RPS6 in epithelial dysplasia and squamous cell carcinoma of the oral cavity, aimed to describe a significant correlation between the expression of the well-established immunologic and oncologic biomarkers, programmed death ligand -1 (PD-L1) and phosphorylated ribosomal protein S6 (RPS6), respectively, in oral epithelial dysplasia (OED). In 52 OSCC and 48 OED cases, p-RPS6 expression was detected in all cases of OSCC and OED, whereas PD-L1 was expressed in 42/48 (87%) OED and in 28/52 (53%) OSCC. The patients with mild OED presented a significantly higher expression of PD-L1 and p-RPS6, when compared to moderately differentiated OSCC patients (P<0.05). They described a significant positive correlation between PD-L1 and p-RPS6 expression in OED and OSCC patients. Their findings suggest that up-regulation of PD-L1 can be related to activation of the mitogenic pathway mTOR in the early events of precancerous lesions as well as in the pathogenesis of OSCC. Their work provides additional supportive evidence that the process of immune modulation can be concurrent with the mitogenic progression of precancerous and tumor cells. Review, the authors included six retrospective cohort studies involving 1,203 patients that met the inclusion criteria. They aimed to explore the tertiary lymphoid structures (TLS) in the tumor microenvironment (TME). TLS were located in the peri-tumoral area (75.4%-84.8%) compared to the intra-tumoral area (33.8%-33.9%). The review showed that the presence of TLS is associated with improved survival in OSCC. They concluded that standardization of methodologies of detecting TLS is imperative to ensure consistency in criteria utilization, thereby facilitating meaningful data comparison. Their work adds to the significance of characterizing tumor inflammation and confirms a long-standing notion among pathologists, that TLS are usually associated with low grade tumors, responsive immune system, or tumors with better prognosis. axis that triggers NF-kB, as a significant driver of tumor growth. They conclude that IL33 may be a prognostic biomarker and therapeutic target in HNSCC, that significantly configures the tumor microenvironment and tumor aggressiveness. They also bring up the role of serum IL33 and ST2, that remains to be further studied in HNSCC, as the soluble form of ST2 may function as a decoy receptor reducing IL-33 biologic activity. This highlights the implications of soluble versus cell bound inflammatory cytokines that may have different biological and translational significance.The five studies presented in the current research topic emphasized traditional, emerging and novel complex biomarker signatures of the immuno-oncologic platform. This area of research focus will help stratify OSCC patients and accordingly open new avenues for better personalized lines of treatment, early detection, and prevention of OSCC.
- 16 June 2025
- Published by Frontiers Media SA in Frontiers in Oral Health
- Vol. 6, 1635675
Open AccessEditorial: Immuno-oncologic biomarker signatures for personalized immunotherapy and immunoprevention in oral squamous cell carcinoma
The development of oral cancer is a multifactorial and complex process (1). The interaction between the mutated oral epithelial cells and the underlying stromal and immune system plays a major role in the process of tumor development and progression. Immunotherapy represents the most recent therapeutic advent in the field with significant improvement in overall survival. Yet, differential patients' responses warrants more understanding of the immuno-oncologic profile of oral cancer.The current research topic in Frontiers oral health-oral cancer aimed to shed light on recent evidence-based immuno-oncologic biomarkers associated with the clinico-pathological features of oral squamous cell carcinoma (OSCC) and potentially cancerous oral lesions. The ultimate goal is for better patients' stratification, and hence more guidance for personalized therapeutic regimens (2).The topic starts with a research manuscript by Sahu et al, titled: 4-Nitroquinoline 1-oxide induces immune cells death to onset early immunosuppression during Oral Squamous Cell Carcinoma Development. In this manuscript the authors present an in vivo model of how the chemical carcinogen modulates an immunosuppressive profile that starts in the oral precancerous stages. Significant decrease in B and T cell populations, specifically CD5+B cell, and gamma/delta-T cell population (γδ-TCR + ) was observed in the spleen in the early stages of development of the precancerous lesions and persisted after OSCC development. Despite the increase in NK, NKT, and lymphoid DC, in peripheral blood there was a decrease in most of the lymphocyte population (T, B, CD5+B cells) during early development, but not later. Concluding that immune cell derangement is not a post-cancerous event, rather, an early event that may persist until tumor development and beyond. In vitro analysis demonstrated B cells to be more susceptible to reduced viability and DNA damage when expos ed to the chemical carcinogen compared to T cells. These findings provide supportive pre-clinical evidence for introducing immunotherapy in initial stages of precancerous lesions, as a preventive strategy for OSCC.To further highlight the onset of immune derangement early in OSCC precursor lesions, the second research manuscript by Hanroongsri, et al, titled: Expression of PD-L1 and p-RPS6 in epithelial dysplasia and squamous cell carcinoma of the oral cavity, aimed to describe a significant correlation between the expression of the well-established immunologic and oncologic biomarkers, programmed death ligand -1 (PD-L1) and phosphorylated ribosomal protein S6 (RPS6), respectively, in oral epithelial dysplasia (OED). In 52 OSCC and 48 OED cases, p-RPS6 expression was detected in all cases of OSCC and OED, whereas PD-L1 was expressed in 42/48 (87%) OED and in 28/52 (53%) OSCC. The patients with mild OED presented a significantly higher expression of PD-L1 and p-RPS6, when compared to moderately differentiated OSCC patients (P<0.05). They described a significant positive correlation between PD-L1 and p-RPS6 expression in OED and OSCC patients. Their findings suggest that up-regulation of PD-L1 can be related to activation of the mitogenic pathway mTOR in the early events of precancerous lesions as well as in the pathogenesis of OSCC. Their work provides additional supportive evidence that the process of immune modulation can be concurrent with the mitogenic progression of precancerous and tumor cells. Review, the authors included six retrospective cohort studies involving 1,203 patients that met the inclusion criteria. They aimed to explore the tertiary lymphoid structures (TLS) in the tumor microenvironment (TME). TLS were located in the peri-tumoral area (75.4%-84.8%) compared to the intra-tumoral area (33.8%-33.9%). The review showed that the presence of TLS is associated with improved survival in OSCC. They concluded that standardization of methodologies of detecting TLS is imperative to ensure consistency in criteria utilization, thereby facilitating meaningful data comparison. Their work adds to the significance of characterizing tumor inflammation and confirms a long-standing notion among pathologists, that TLS are usually associated with low grade tumors, responsive immune system, or tumors with better prognosis. axis that triggers NF-kB, as a significant driver of tumor growth. They conclude that IL33 may be a prognostic biomarker and therapeutic target in HNSCC, that significantly configures the tumor microenvironment and tumor aggressiveness. They also bring up the role of serum IL33 and ST2, that remains to be further studied in HNSCC, as the soluble form of ST2 may function as a decoy receptor reducing IL-33 biologic activity. This highlights the implications of soluble versus cell bound inflammatory cytokines that may have different biological and translational significance.The five studies presented in the current research topic emphasized traditional, emerging and novel complex biomarker signatures of the immuno-oncologic platform. This area of research focus will help stratify OSCC patients and accordingly open new avenues for better personalized lines of treatment, early detection, and prevention of OSCC.
- Open Access
- 16 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 12309
Identification of Functional Immune Biomarkers in Breast Cancer Patients
Cancer immunotherapy has emerged as an effective, personalized treatment for certain patients, particularly for those with hematological malignancies. However, its efficacy in breast cancer has been marginal—perhaps due to cold, immune-excluded, or immune-desert tumors. Natural killer T (NKT) cells play a critical role in cancer immune surveillance and are reduced in cancer patients. Thus, we hypothesized that NKT cells could serve as a surrogate marker for immune function. In order to assess which breast cancer patients would likely benefit from immune cell-based therapies, we have developed a quantitative method to rapidly assess NKT function using stimulation with artificial antigen presenting cells followed by quantitative real-time PCR for IFN-γ. We observed a significant reduction in the percentage of circulating NKT cells in breast cancer patients, compared to healthy donors; however, the majority of patients had functional NKT cells. When we compared BC patients with highly functional NKT cells, as indicated by high IFN-γ induction, to those with little to no induction, following stimulation of NKT cells, there was no significant difference in NKT cell number between the groups, suggesting functional loss has more impact than physical loss of this subpopulation of T cells. In addition, we assessed the percentage of tumor-infiltrating lymphocytes and PD-L1 expression within the tumor microenvironment in the low and high responders. Further characterization of immune gene signatures in these groups identified a concomitant decrease in the induction of TNFα, LAG3, and LIGHT in the low responders. We next investigated the mechanisms by which breast cancers suppress NKT-mediated anti-tumor immune responses. We found that breast cancers secrete immunosuppressive lipids, and treatment with commonly prescribed medications that modulate lipid metabolism, can reduce tumor growth and restore NKT cell responses.
- 16 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 12309
Open AccessIdentification of Functional Immune Biomarkers in Breast Cancer Patients
Cancer immunotherapy has emerged as an effective, personalized treatment for certain patients, particularly for those with hematological malignancies. However, its efficacy in breast cancer has been marginal—perhaps due to cold, immune-excluded, or immune-desert tumors. Natural killer T (NKT) cells play a critical role in cancer immune surveillance and are reduced in cancer patients. Thus, we hypothesized that NKT cells could serve as a surrogate marker for immune function. In order to assess which breast cancer patients would likely benefit from immune cell-based therapies, we have developed a quantitative method to rapidly assess NKT function using stimulation with artificial antigen presenting cells followed by quantitative real-time PCR for IFN-γ. We observed a significant reduction in the percentage of circulating NKT cells in breast cancer patients, compared to healthy donors; however, the majority of patients had functional NKT cells. When we compared BC patients with highly functional NKT cells, as indicated by high IFN-γ induction, to those with little to no induction, following stimulation of NKT cells, there was no significant difference in NKT cell number between the groups, suggesting functional loss has more impact than physical loss of this subpopulation of T cells. In addition, we assessed the percentage of tumor-infiltrating lymphocytes and PD-L1 expression within the tumor microenvironment in the low and high responders. Further characterization of immune gene signatures in these groups identified a concomitant decrease in the induction of TNFα, LAG3, and LIGHT in the low responders. We next investigated the mechanisms by which breast cancers suppress NKT-mediated anti-tumor immune responses. We found that breast cancers secrete immunosuppressive lipids, and treatment with commonly prescribed medications that modulate lipid metabolism, can reduce tumor growth and restore NKT cell responses.
- Open Access
- 6 June 2024
- Published by Frontiers Media SA in Frontiers in Oral Health
- Vol. 5, 1408072
Histological pattern of tumor inflammation and stromal density correlate with patient demographics and immuno-oncologic transcriptional profile in oral squamous cell carcinoma
Introduction: Oral squamous cell carcinoma (OSCC) is the most prevalent oral malignancy, with emerging interest in the characterization of its tumor microenvironment. Herein, we present a comprehensive histological analysis of OSCC stromal density and inflammation and their relationship with patient demographics, clinicopathologic features and immuno-oncologic signatures.Materials-methods: Eighty-seven completely excised OSCC tissues were prospectively collected and scored for histopathologic inflammatory subtypes [HIS]—inflamed (INF), immune-excluded (IE) and immune-desert (ID), peritumoral stromal inflammation (PTSI), and peritumoral stromal fibrosis (PTSF). Scoring of inflammation was complemented by Semaphorin 4D immunohistochemistry. NanoString differential gene expression (DGE) analysis was conducted for eight OSCC cases representative of the inflammatory and stromal subtypes and the demographic groups.Results: PTSF correlated with male gender (p = 0.0043), smoking (p = 0.0455), alcohol consumption (p = 0.0044), increased tumor size (p = 0.0054), and advanced stage (p = 0.002). On the contrary, PTSI occurred predominantly in females (p = 0.0105), non-drinkers (p = 0.0329), and small tumors (p = 0.0044). Transcriptionally, decreased cytokine signaling, and oncogenic pathway activation were observed in HIS-IE. Smokers and males displayed decreased global immune-cell levels and myeloid-cell predominance.Conclusion: Our work describes OSCC stromal and inflammatory phenotypes in correlation with distinct patient groups and DGE, highlighting the translational potential of characterizing the tumor microenvironment for optimal patient stratification.
- 6 June 2024
- Published by Frontiers Media SA in Frontiers in Oral Health
- Vol. 5, 1408072
Open AccessHistological pattern of tumor inflammation and stromal density correlate with patient demographics and immuno-oncologic transcriptional profile in oral squamous cell carcinoma
Introduction: Oral squamous cell carcinoma (OSCC) is the most prevalent oral malignancy, with emerging interest in the characterization of its tumor microenvironment. Herein, we present a comprehensive histological analysis of OSCC stromal density and inflammation and their relationship with patient demographics, clinicopathologic features and immuno-oncologic signatures.Materials-methods: Eighty-seven completely excised OSCC tissues were prospectively collected and scored for histopathologic inflammatory subtypes [HIS]—inflamed (INF), immune-excluded (IE) and immune-desert (ID), peritumoral stromal inflammation (PTSI), and peritumoral stromal fibrosis (PTSF). Scoring of inflammation was complemented by Semaphorin 4D immunohistochemistry. NanoString differential gene expression (DGE) analysis was conducted for eight OSCC cases representative of the inflammatory and stromal subtypes and the demographic groups.Results: PTSF correlated with male gender (p = 0.0043), smoking (p = 0.0455), alcohol consumption (p = 0.0044), increased tumor size (p = 0.0054), and advanced stage (p = 0.002). On the contrary, PTSI occurred predominantly in females (p = 0.0105), non-drinkers (p = 0.0329), and small tumors (p = 0.0044). Transcriptionally, decreased cytokine signaling, and oncogenic pathway activation were observed in HIS-IE. Smokers and males displayed decreased global immune-cell levels and myeloid-cell predominance.Conclusion: Our work describes OSCC stromal and inflammatory phenotypes in correlation with distinct patient groups and DGE, highlighting the translational potential of characterizing the tumor microenvironment for optimal patient stratification.
- 12 July 2023
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 136 (5) , 612-622
Immuno-oncologic signature of malignant transformation in oral squamous cell carcinoma
- 12 July 2023
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 136 (5) , 612-622
Immuno-oncologic signature of malignant transformation in oral squamous cell carcinoma
- 15 February 2023
- Published by Elsevier in Oral and Maxillofacial Surgery Clinics of North America
- Vol. 35 (2) , 261-270
Plasma Cell Gingivitis and Its Mimics
- 15 February 2023
- Published by Elsevier in Oral and Maxillofacial Surgery Clinics of North America
- Vol. 35 (2) , 261-270
Plasma Cell Gingivitis and Its Mimics
- Open Access
- 12 September 2022
- Published by Frontiers Media SA in Frontiers in Oral Health
- Vol. 3, 993638
Cytokine profiling in plasma distinguishes the histological inflammatory subtype of head and neck squamous cell carcinoma and a novel regulatory role of osteopontin
Head and neck squamous cell carcinoma (HNSCC) can be classified according to the histological inflammatory subtype (HIS) into inflamed (HIS-INF) or immune excluded (HIS-IE). HIS-IE was previously associated with higher levels of soluble Semaphorin 4D (HsS4D) in plasma, and higher transcriptional levels of osteopontin (OPN) in the tumor tissue, compared to HIS-INF. The goal of the current study is to investigate whether the HIS inflammatory subtype can be distinguished by a differential cytokine panel in peripheral blood. Retrospectively collected five HIS-INF and five HIS-IE tumor tissue with paired plasma were included in the study. Five healthy donors (HD) and five autoimmune/chronic inflammatory conditions (AI/CI) were controls. The ELISA-Luminex™ system was used to detect 40 traditional cytokines in plasma. Human cytokine array (104 cytokines) was used for the conditioned medium (CM) of the HNSCC HN6 cell line. Semaphorin 4D (Sema4D) siRNA and recombinant human osteopontin (rh-OPN) were used to investigate the effect of OPN on Sema4D expression. The HIS-IE cytokine profile was higher than HIS-INF but comparable to AI/CI. HIS-INF had the lowest cytokine levels. HIS-IE was differentially higher in IP-10 and IL8 compared to HD, while HIS-INF was higher in IL-10. Sema4D inhibition in HN6 resulted in a decrease of OPN in the CM of HN6, and treatment with rh-OPN rescued Sema4D in HN6 cell lysate and associated CM. In conclusion, the current work demonstrates a novel association between the HIS subtypes and a differential pattern of cytokine expression in plasma. These findings can open new avenues for HNSCC patient stratification and hence provide better personalized treatment.
- 12 September 2022
- Published by Frontiers Media SA in Frontiers in Oral Health
- Vol. 3, 993638
Open AccessCytokine profiling in plasma distinguishes the histological inflammatory subtype of head and neck squamous cell carcinoma and a novel regulatory role of osteopontin
Head and neck squamous cell carcinoma (HNSCC) can be classified according to the histological inflammatory subtype (HIS) into inflamed (HIS-INF) or immune excluded (HIS-IE). HIS-IE was previously associated with higher levels of soluble Semaphorin 4D (HsS4D) in plasma, and higher transcriptional levels of osteopontin (OPN) in the tumor tissue, compared to HIS-INF. The goal of the current study is to investigate whether the HIS inflammatory subtype can be distinguished by a differential cytokine panel in peripheral blood. Retrospectively collected five HIS-INF and five HIS-IE tumor tissue with paired plasma were included in the study. Five healthy donors (HD) and five autoimmune/chronic inflammatory conditions (AI/CI) were controls. The ELISA-Luminex™ system was used to detect 40 traditional cytokines in plasma. Human cytokine array (104 cytokines) was used for the conditioned medium (CM) of the HNSCC HN6 cell line. Semaphorin 4D (Sema4D) siRNA and recombinant human osteopontin (rh-OPN) were used to investigate the effect of OPN on Sema4D expression. The HIS-IE cytokine profile was higher than HIS-INF but comparable to AI/CI. HIS-INF had the lowest cytokine levels. HIS-IE was differentially higher in IP-10 and IL8 compared to HD, while HIS-INF was higher in IL-10. Sema4D inhibition in HN6 resulted in a decrease of OPN in the CM of HN6, and treatment with rh-OPN rescued Sema4D in HN6 cell lysate and associated CM. In conclusion, the current work demonstrates a novel association between the HIS subtypes and a differential pattern of cytokine expression in plasma. These findings can open new avenues for HNSCC patient stratification and hence provide better personalized treatment.
- 1 November 2021
- Published by Elsevier in Journal of Stomatology Oral and Maxillofacial Surgery
- Vol. 122 (5) , 516-520
Central compact osteoma of the mandible: case report featuring unusual radiographic and computed tomographic presentations and brief literature review
- 1 November 2021
- Published by Elsevier in Journal of Stomatology Oral and Maxillofacial Surgery
- Vol. 122 (5) , 516-520
Central compact osteoma of the mandible: case report featuring unusual radiographic and computed tomographic presentations and brief literature review
- Open Access
Deletion Mutants of Francisella Phagosomal Transporters FptA and FptF Are Highly Attenuated for Virulence and Are Protective Against Lethal Intranasal Francisella LVS Challenge in a Murine Model of Respiratory Tularemia
Francisella tularensis (Ft) is a Gram-negative, facultative intracellular bacterium that is a Tier 1 Select Agent of concern for biodefense for which there is no licensed vaccine. A subfamily of 9 Francisella phagosomal transporter (fpt) genes belonging to the Major Facilitator Superfamily of transporters was identified as critical to pathogenesis and potential targets for attenuation and vaccine development. We evaluated the attenuation and protective capacity of LVS derivatives with deletions of the fptA and fptF genes in the C57BL/6J mouse model of respiratory tularemia. LVSΔfptA and LVSΔfptF were highly attenuated with LD50 values of >20 times that of LVS when administered intranasally and conferred 100% protection against lethal challenge. Immune responses to the fpt mutant strains in mouse lungs on day 6 post-infection were substantially modified compared to LVS and were associated with reduced organ burdens and reduced pathology. The immune responses to LVSΔfptA and LVSΔfptF were characterized by decreased levels of IL-10 and IL-1β in the BALF versus LVS, and increased numbers of B cells, αβ and γδ T cells, NK cells, and DCs versus LVS. These results support a fundamental requirement for FptA and FptF in the pathogenesis of Ft and the modulation of the host immune response.
Open AccessDeletion Mutants of Francisella Phagosomal Transporters FptA and FptF Are Highly Attenuated for Virulence and Are Protective Against Lethal Intranasal Francisella LVS Challenge in a Murine Model of Respiratory Tularemia
Francisella tularensis (Ft) is a Gram-negative, facultative intracellular bacterium that is a Tier 1 Select Agent of concern for biodefense for which there is no licensed vaccine. A subfamily of 9 Francisella phagosomal transporter (fpt) genes belonging to the Major Facilitator Superfamily of transporters was identified as critical to pathogenesis and potential targets for attenuation and vaccine development. We evaluated the attenuation and protective capacity of LVS derivatives with deletions of the fptA and fptF genes in the C57BL/6J mouse model of respiratory tularemia. LVSΔfptA and LVSΔfptF were highly attenuated with LD50 values of >20 times that of LVS when administered intranasally and conferred 100% protection against lethal challenge. Immune responses to the fpt mutant strains in mouse lungs on day 6 post-infection were substantially modified compared to LVS and were associated with reduced organ burdens and reduced pathology. The immune responses to LVSΔfptA and LVSΔfptF were characterized by decreased levels of IL-10 and IL-1β in the BALF versus LVS, and increased numbers of B cells, αβ and γδ T cells, NK cells, and DCs versus LVS. These results support a fundamental requirement for FptA and FptF in the pathogenesis of Ft and the modulation of the host immune response.
- Open Access
- 11 March 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile
Semaphorin 4D (Sema4D) is a glycoprotein that is expressed by several tumors and immune cells. It can function as a membrane bound protein or as a cleaved soluble protein (sSema4D). We sought to investigate the translational potential of plasma sSema4D as an immune marker in plasma of patients with head and neck squamous cell carcinoma (HNSCC). Paired peripheral blood and tumor tissue samples of 104 patients with HNSCC were collected at the same time point to allow for real time analysis. Scoring of the histological inflammatory subtype (HIS) was carried out using Sema4D immunohistochemistry on the tumor tissue. sSema4D was detected in plasma using direct ELISA assay. Defining elevated sSema4D as values above the 95thpercentile in healthy controls, our data showed that sSema4D levels in plasma were elevated in 25.0% (95% CI, 16.7–34.9%) of the patients with HNSCC and showed significant association with HIS immune excluded (HIS-IE) (p = 0.007), Sema4D+vetumor cells (TCs) (p = 0.018) and PD-L1+veimmune cells (ICs) (p = 0.038). A multi-variable logistic regression analysis showed that HIS was significantly (P = 0.004) associated with elevated sSema4D, an association not explained by available patient-level factors. Using the IO-360 nanoString platform, differential gene expression (DGE) analysis of 10 HNSCC tumor tissues showed that patients with high sSema4D in plasma (HsS4D) clustered as IFN-γnegative tumor immune signature and were mostly HIS-IE. The IC type in the HsS4D paired tumor tissue was predominantly myeloid, while the lymphoid compartment was higher in the low sSema4D (LsS4D). The Wnt signaling pathway was upregulated in the HsS4D group. Further analysis using the IO-360, 770 gene set, showed significant non-inflamed profile of the HsS4D tumors compared to the LsS4D. In conclusion, our data reveals an association between sSema4D and the histological inflammatory subtype.
- 11 March 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Open AccessSoluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile
Semaphorin 4D (Sema4D) is a glycoprotein that is expressed by several tumors and immune cells. It can function as a membrane bound protein or as a cleaved soluble protein (sSema4D). We sought to investigate the translational potential of plasma sSema4D as an immune marker in plasma of patients with head and neck squamous cell carcinoma (HNSCC). Paired peripheral blood and tumor tissue samples of 104 patients with HNSCC were collected at the same time point to allow for real time analysis. Scoring of the histological inflammatory subtype (HIS) was carried out using Sema4D immunohistochemistry on the tumor tissue. sSema4D was detected in plasma using direct ELISA assay. Defining elevated sSema4D as values above the 95thpercentile in healthy controls, our data showed that sSema4D levels in plasma were elevated in 25.0% (95% CI, 16.7–34.9%) of the patients with HNSCC and showed significant association with HIS immune excluded (HIS-IE) (p = 0.007), Sema4D+vetumor cells (TCs) (p = 0.018) and PD-L1+veimmune cells (ICs) (p = 0.038). A multi-variable logistic regression analysis showed that HIS was significantly (P = 0.004) associated with elevated sSema4D, an association not explained by available patient-level factors. Using the IO-360 nanoString platform, differential gene expression (DGE) analysis of 10 HNSCC tumor tissues showed that patients with high sSema4D in plasma (HsS4D) clustered as IFN-γnegative tumor immune signature and were mostly HIS-IE. The IC type in the HsS4D paired tumor tissue was predominantly myeloid, while the lymphoid compartment was higher in the low sSema4D (LsS4D). The Wnt signaling pathway was upregulated in the HsS4D group. Further analysis using the IO-360, 770 gene set, showed significant non-inflamed profile of the HsS4D tumors compared to the LsS4D. In conclusion, our data reveals an association between sSema4D and the histological inflammatory subtype.